Phase

Phase, Inc. is at the forefront of the microfluidics industry with its advanced 3D printing platform designed to revolutionize the $17 billion market. The company specializes in creating microfluidic devices, which are essential for developing next-generation therapeutics and diagnostics. These devices serve as the digital age's test tubes, facilitating groundbreaking medical research. Phase, Inc. employs proprietary LE3D printing technology that offers unmatched biomimicry, using biocompatible materials not currently 3D printable by competitors. This technology is complemented by a user-friendly interface that allows non-engineers to design and create microfluidics with ease. The company is backed by an NIH grant and collaborates with the Virginia Tech Wake Forest School of Biomedical Engineering and Sciences to develop microfluidic devices for brain cancer treatment research. Phase, Inc. operates in the biomedical engineering sector, serving researchers and scientists focused on medical breakthroughs. Its business model revolves around leveraging its unique 3D printing capabilities to provide cutting-edge solutions in microfluidics, generating revenue through partnerships and grants. Keywords: microfluidics, 3D printing, biomimicry, therapeutics, diagnostics, biocompatible, NIH grant, Virginia Tech, biomedical engineering, brain cancer.